Charles Bobrinskoy
Ariel Focus Fund
Charles Bobrinskoy Zimmer Biomet Holdings Inc stake
total: 59
Ariel Focus Fund ZBH trades
- Total transactions:
- 14
- New positions:
- 1
- Sold out:
- 1
- Added:
- 3
- Reduced:
- 9
- Held since:
- 2019 Q3
- Held for:
- 16 quarters
- Latest activity:
- 2023 Q3
According to 2026 Q2 report, Charles Bobrinskoy doesn't hold any Zimmer Biomet Holdings Inc (ZBH) shares. To date, the estimated cost basis is nearly $137.43 for "buy" trades and estimated average "sell" price is $134.47. Ariel Focus Fund first purchased ZBH in 2019 Q3, initially acquiring 19,700 shares. Since the initial investment in Zimmer Biomet Holdings Inc (ZBH), Ariel Focus Fund has made 13 more transactions.
When did Charles Bobrinskoy sell Zimmer Biomet Holdings Inc (ZBH)?
Charles Bobrinskoy sold off the entire Zimmer Biomet Holdings Inc (ZBH) position in 2023 Q3.
When did Charles Bobrinskoy buy Zimmer Biomet Holdings Inc (ZBH)?
Charles Bobrinskoy first invested in Zimmer Biomet Holdings Inc (ZBH) in 2019 Q3 at the reported quarter-end price of $137.27 per share.
What's the cost basis of Ariel Focus Fund's ZBH stake?
The estimated cost basis for Zimmer Biomet Holdings Inc (ZBH) stake is around $137.43 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $137.43
- Weighted AVG sell price:
- $134.47
Charles Bobrinskoy's historical trades in Zimmer Biomet Holdings Inc
14 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2023 Q3
|
0.00%
|
0
|
$145.60
|
|
-100% (-2,873)
|
-0.63%
|
|
2023 Q2
|
0.63%
|
2,873
|
$145.60
|
$418,309
|
-57.80% (-3,935)
|
-0.87%
|
|
2023 Q1
|
1.34%
|
6,808
|
$129.20
|
$879,594
|
-13.06% (-1,023)
|
-0.21%
|
|
2022 Q4
|
1.61%
|
7,831
|
$127.50
|
$998,452
|
-30.91% (-3,503)
|
-0.79%
|
|
2022 Q3
|
2.09%
|
11,334
|
$104.55
|
$1,184,970
|
-19.92% (-2,820)
|
-0.48%
|
|
2022 Q1
|
2.43%
|
14,154
|
$127.90
|
$1,810,297
|
-9.61% (-1,504)
|
-0.27%
|
|
2021 Q4
|
2.80%
|
15,658
|
$127.04
|
$1,989,192
|
+9.15% (+1,313)
|
+0.24%
|
|
2021 Q3
|
3.41%
|
14,345
|
$146.36
|
$2,099,534
|
-2.75% (-405)
|
-0.09%
|
|
2021 Q2
|
3.56%
|
14,750
|
$160.82
|
$2,372,095
|
+2.08% (+300)
|
+0.07%
|
|
2020 Q4
|
4.18%
|
$154.09
|
-18.82% (-3,350)
|
|||
|
2020 Q3
|
5.44%
|
$136.14
|
-5.82% (-1,100)
|
|||
|
2020 Q2
|
4.91%
|
$119.36
|
-7.80% (-1,600)
|
|||
|
2019 Q4
|
4.91%
|
$149.68
|
+4.06% (+800)
|
|||
|
2019 Q3
|
4.80%
|
$137.27
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.